Global Biosimulation Market Overview

The global Biosimulation Market size was valued at USD 3.73 Billion in 2022 and is projected to reach USD 11.73 Billion by 2030, growing at a CAGR of 15.4% from 2023 to 2030.

Biosimulation is a predictive technological tool that is used in the discovery stage which signifies the future outcomes of the current experimental trials. It is also referred to as model-based drug development and it has the ability to make a data-driven decision at all stages of drug development by using the quantitative framework. The quality of the predictions of the model-based experiment trials strongly depends on the quality model. It is a promising technology that is used in pharmaceutical research to enhance the cycle of drug discovery and development. The researchers are more engaged in developing artificial organs through computer simulation technology and mathematical modeling.  Biosimulation technologies play a crucial role in developing drugs for the treatment of cancer and cardiovascular diseases. Due to the growing prevalence of chronic diseases across the world, rising advanced techniques, and high government funding that supports the growth of the market of biosimulation.

Biosimulation Market

Market Dynamics And Factors For Biosimulation Market

Drivers:

Growth in the Development of Biologics and Biosimilar

The demand for biologics across the healthcare sectors is increased is the major factor that supports the growth of the biosimulation market. In the last few years growing the incidence of chronic diseases and their diagnosis worldwide. For instance, Statista stated that around 19.2 million new cancer cases were present in 2020 in the world. According to WHO, 41 million deaths occur due to non-communicable diseases in 2021. The following diagram shows that death occurs due to non-communicable diseases in 2021.

Thus, due to the growing prevalence of diseases, the market players rising their investment in the research and development of biologics. For instance, Cadila Pharmaceuticals launched two similar biologics such as NuPTH and Cadalimab in the Indian market in October 2020. Moreover, technological advancement, and rising government funding in the R&D activities of oral biologics which rising the demand for biosimulation technologies that provide growth for the biosimulation market.

Restraints:

Lack of Standardisation For Model Representation

The lack of standardization for model representation of the biosimulation technology is the key factor that restricts the growth of the biosimulation market. Biosimulation utilizes different types of models, tools, and languages for capturing and processing various aspects of biological processes. For building and managing complex biosimulation systems, advanced technology has improved the computational power of biomedical researchers. As the model and simulation grow in complexity, it is more difficult to share, manage and edit models for researchers. The problem of sharing models becomes more critical with the lack of standardization for model representation which hampers the growth of the biosimulation market.

Opportunity:

Growing Government Funding In The R&D Activities

The government of various countries’ rising investment in the research and development of drugs is providing a lucrative opportunity for the biosimulation market during the forecast period.  The research and development sectors spent on the discovery and evaluation of the new drug.  Owing to the growing prevalence of chronic diseases with the death rate, rising concern about the diseases among people.  Thus, for the treatment of these diseases, the government funds more for the development of novel drugs. For instance, according to Statista, the Germany and United States are the leading sources in the investment of research and development, and they putting 1.5 billion and 2 billion into the development of the covid-19 vaccines respectively. Thus, government investment offers a remunerative opportunity for the biosimulation market in the forecast period.

Segmentation Analysis Of Biosimulation Market

By Product Type, the software segment is expected to have the maximum share in the biosimulation market during the forecast period. The biosimulation software includes PBPK modeling and simulation software, lecular modeling and simulation software, trial design software, PK/PD modeling and simulation software, toxicity prediction software, and other biosimulation software. In pharmaceutical, biotechnological companies, and research organizations there is increased demand for biosimulation due to they are continuously engaged in the research and development of different kinds of novel drugs. The growing government support for the activities related to research studies. The market players installing the new advanced technology in biosimulation software to improve the drug development process. For instance, In June 2022, a global leader in biosimulation, Certara launched a new version of biosimulation software for the development of novel biologics. This latest version helps to tackle challenges in drug discovery and development with complex biologics. Thus, the software has maximum growth in the biosimulation market.

By Application, drug development is projected to have the largest share in the biosimulation market during the analysis period. The pharmaceutical, biotechnological, and research organizations increasing biosimulation adoption for controlling the costs in the drug development process. The US FDA stated that biosimulation is the most useful tool in the drug development process. In the last few decades, the prevalence of chronic diseases is increased in the world. Thus, the government of various countries also healthcare organization major in investing in drug development. Clinical studies are the most crucial part of drug development. According to Statista in the recent year constantly rising registered number of clinical trials. As of 28 March 2022, there were more than 409 thousand clinical studies registered worldwide. Henceforth, due to the growing drug development processes, the adoption of biosimulation is increased which propels the growth of the biosimulation market.

By End-Users, the pharmaceutical and biotechnological companies have the maximum share in the biosimulation market. The pharmaceutical and biotechnological companies continuously engaged in the drug discovery and development process. The following figure shows the expenditure of the total US pharmaceutical companies in research and development from 2017-2021.

Moreover, due to the rising prevalence of chronic diseases, the government increasing its funding for the development of pharmaceutical as well as biotechnological companies. Thus, the adoption of biosimulation is dominant in pharmaceutical and biotechnological companies which boosts the biosimulation market.

Regional Analysis Of Biosimulation Market

North America is the dominant region in the biosimulation market owing to growing the research and development of novel drugs. In this region rising the prevalence of chronic diseases such as cancer, and cardiovascular diseases, the government, and healthcare sectors increasing their investment in the development of the new drug. For instance, as per the report of the Centers for disease control and prevention, there were 697,000 people died in the year 2020 in United State. The US is dominant in North America for the biosimulation market. The Food and Drug Administration (FDA) of the US strongly suggested the simulation process in drug discovery and development. For instance, according to the report of theclinicaltrials.gov. there are 134,116 clinical trials going on in the United State as of 8th August 2022.  The covid-19 changed the demand for clinical trials in the US. The major players in this region adopting digital and automation technologies. In May 2022, the US FDA certified the renewal license of DILIsym software platform of Simulations Plus a key provider of modeling and simulation software and services for pharmaceutical safety and efficacy. Thus, the growing launching of new drugs and growing government funding in the research and development of the drugs rising the demand for biosimulation technologies that propel the growth of the market biosimulation in the North American region.

The Asia Pacific is the second-dominated region in the market of biosimulation owing to the high presence of healthcare and pharmaceutical industries. The APAC region has the largest population with a high prevalence of chronic diseases such as heart disease, cancer, diabetes, and others. For instance, according to Statista, there were over 4.5 million new cancer cases in China. The following figure shows the number of cancer patients with the type of cancer in China in the year 2020.

Due to this growing prevalence of such types of chronic diseases, market players and governments of various countries in the APAC region are more investing in the research and development of the new drug. For instance, in 2020 about around 722 clinical trials of the cancer drug were conducted in China. Thus, the growing R&D of the novel drug increases the demand for biosimulation technology that boosts the biosimulation market of the APAC region.

Europe is a rapidly growing region in the market of biosimulation due to growing research and development activities and high healthcare expenditure. In the Europe region growing prevalence of cancer thus the major players of this region are highly invested in the development of the drug. For instance, according to World Health Organization (WHO), there were a total of 2.7 million new cases of cancer excluding non-melanoma skin cancers and 1.3 million death occurs due to cancer. Thus, the government of Europe is more invested in the development of novel drugs. The pharmaceutical and biotechnological companies in this region increasing the launching of new drugs which rises the demand for biosimulation and also the growing adoption of the developed technology which supports the growth of the biosimulation market over the forecast period.

Covid-19 Impact Analysis On Biosimulation Market

COVID-19 began in Wuhan (China) in December 2019 and has since rapidly grown around the globe. In terms of confirmed cases and reported deaths, the US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are among the countries that have been most severely impacted. Because of the lockdowns, travel restrictions, and business closures, COVID-19 has had an impact on the businesses and industries of numerous nations. The covid-19 has had a positive impact on the healthcare system. During the pandemic, pharmaceutical, as well as biotechnological companies constantly engaged in research and development activity. The merging and the acquisition also increased to improve the development process of the drugs for the treatment of the covid-19 and other non-communicable diseases. For instance, the National Research Council of Canada and China-based CanSino Biologics made a partnership in May 2020 for the clinical development of a COVID-19 vaccine in Canada. So, the demand for biosimulation is high during the pandemic. Thus, Covid-19 has a positive impact on the biosimulation market.

Top Key Players Covered In Biosimulation Market

  • Certara(USA)
  • Dassault Systemes (France)
  • Advanced Chemistry Development (Canada)
  • Simulation Plus (California)
  • Schrodinger, Inc. (US)
  • Chemical Computing Group ULC (Canada)
  • Physiomics Plc (UK)
  • Rosa & Co. LLC (US)
  • BioSimulation Consulting Inc.
  • Genedata AG (Switzerland)
  • Instem Group of Companies (USA)
  • PPD, Inc. (North Carolina)
  • Yokogawa Insilico Biotechnology GmbH (Germany)
  • Immunetrics (US), and other major players.

Key Industry Development In The Biosimulation Market

In August 2020, For Covid-19 vaccines, Certara started developing the Quantitative Systems Pharmacology biosimulation software.

In June 2020, Certara launched new Phoenix Biosimulation software that improves the quality, time-saving and enhanced efficiency in the toxicokinetic and pharmacokinetic/pharmacodynamic modeling.

Global Biosimulation Market

Base Year:

2022

Forecast Period:

2023-2030

Historical Data :

2017 to 2022

Market Size in 2022:

USD 3.73 Bn.

Forecast Period 2023-30 CAGR:

15.4%

Market Size in 2030:

USD 11.73 Bn.

Segments Covered:

By Product Type

  • Software
  • Services

By Application

  • Drug Discovery
  • Drug Development
  • Other Application

By End-Users

  • Pharma & Biotech Companies
  • Contract Research Organizations
  • Academic Research Institutions
  • Regulatory Authorities

By Region

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:

  • Growth in the Development of Biologics and Biosimilar

Key Market Restraints:

  • Lack of Standardisation For Model Representation

Key Opportunities:

  • Growing Government Funding In The R&D Activities

Companies Covered in the report:

  • Certara (USA), Dassault Systemes (France), Advanced Chemistry Development (Canada), Simulation Plus (California), Schrodinger, Inc. (US), and Other major players.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Test Type
 3.2 By Application

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Biosimulation Market by Test Type
 5.1 Biosimulation Market Overview Snapshot and Growth Engine
 5.2 Biosimulation Market Overview
 5.3 ELISA
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 ELISA: Geographic Segmentation
 5.4 Colorimetric
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Colorimetric: Geographic Segmentation
 5.5 Spectrophotometric
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Spectrophotometric: Geographic Segmentation

Chapter 6: Biosimulation Market by Application
 6.1 Biosimulation Market Overview Snapshot and Growth Engine
 6.2 Biosimulation Market Overview
 6.3 Hospital
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Hospital: Geographic Segmentation
 6.4 Laboratory
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Laboratory: Geographic Segmentation

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Positioning
  7.1.2 Biosimulation Sales and Market Share By Players
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Biosimulation Industry Concentration Ratio (CR5 and HHI)
  7.1.6 Top 5 Biosimulation Players Market Share
  7.1.7 Mergers and Acquisitions
  7.1.8 Business Strategies By Top Players
 7.2 CERTARA
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Operating Business Segments
  7.2.5 Product Portfolio
  7.2.6 Business Performance
  7.2.7 Key Strategic Moves and Recent Developments
  7.2.8 SWOT Analysis
 7.3 DASSAULT SYSTEMES
 7.4 ADVANCED CHEMISTRY DEVELOPMENT
 7.5 SIMULATION PLUS
 7.6 SCHRODINGER
 7.7 INC.
 7.8 CHEMICAL COMPUTING GROUP ULC
 7.9 PHYSIOMICS PLC
 7.10 ROSA & CO. LLC
 7.11 BIOSIMULATION CONSULTING INC.
 7.12 GENEDATA AG
 7.13 INSTEM GROUP OF COMPANIES
 7.14 PPD INC.
 7.15 YOKOGAWA INSILICO BIOTECHNOLOGY GMBH
 7.16 IMMUNETRICS
 7.17 OTHER MAJOR PLAYERS

Chapter 8: Global Biosimulation Market Analysis, Insights and Forecast, 2016-2028
 8.1 Market Overview
 8.2 Historic and Forecasted Market Size By Test Type
  8.2.1 ELISA
  8.2.2 Colorimetric
  8.2.3 Spectrophotometric
 8.3 Historic and Forecasted Market Size By Application
  8.3.1 Hospital
  8.3.2 Laboratory

Chapter 9: North America Biosimulation Market Analysis, Insights and Forecast, 2016-2028
 9.1 Key Market Trends, Growth Factors and Opportunities
 9.2 Impact of Covid-19
 9.3 Key Players
 9.4 Key Market Trends, Growth Factors and Opportunities
 9.4 Historic and Forecasted Market Size By Test Type
  9.4.1 ELISA
  9.4.2 Colorimetric
  9.4.3 Spectrophotometric
 9.5 Historic and Forecasted Market Size By Application
  9.5.1 Hospital
  9.5.2 Laboratory
 9.6 Historic and Forecast Market Size by Country
  9.6.1 U.S.
  9.6.2 Canada
  9.6.3 Mexico

Chapter 10: Europe Biosimulation Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Test Type
  10.4.1 ELISA
  10.4.2 Colorimetric
  10.4.3 Spectrophotometric
 10.5 Historic and Forecasted Market Size By Application
  10.5.1 Hospital
  10.5.2 Laboratory
 10.6 Historic and Forecast Market Size by Country
  10.6.1 Germany
  10.6.2 U.K.
  10.6.3 France
  10.6.4 Italy
  10.6.5 Russia
  10.6.6 Spain
  10.6.7 Rest of Europe

Chapter 11: Asia-Pacific Biosimulation Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Test Type
  11.4.1 ELISA
  11.4.2 Colorimetric
  11.4.3 Spectrophotometric
 11.5 Historic and Forecasted Market Size By Application
  11.5.1 Hospital
  11.5.2 Laboratory
 11.6 Historic and Forecast Market Size by Country
  11.6.1 China
  11.6.2 India
  11.6.3 Japan
  11.6.4 Singapore
  11.6.5 Australia
  11.6.6 New Zealand
  11.6.7 Rest of APAC

Chapter 12: Middle East & Africa Biosimulation Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Test Type
  12.4.1 ELISA
  12.4.2 Colorimetric
  12.4.3 Spectrophotometric
 12.5 Historic and Forecasted Market Size By Application
  12.5.1 Hospital
  12.5.2 Laboratory
 12.6 Historic and Forecast Market Size by Country
  12.6.1 Turkey
  12.6.2 Saudi Arabia
  12.6.3 Iran
  12.6.4 UAE
  12.6.5 Africa
  12.6.6 Rest of MEA

Chapter 13: South America Biosimulation Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Test Type
  13.4.1 ELISA
  13.4.2 Colorimetric
  13.4.3 Spectrophotometric
 13.5 Historic and Forecasted Market Size By Application
  13.5.1 Hospital
  13.5.2 Laboratory
 13.6 Historic and Forecast Market Size by Country
  13.6.1 Brazil
  13.6.2 Argentina
  13.6.3 Rest of SA

Chapter 14 Investment Analysis

Chapter 15 Analyst Viewpoint and Conclusion

Global Biosimulation Market

Base Year:

2022

Forecast Period:

2023-2030

Historical Data :

2017 to 2022

Market Size in 2022:

USD 3.73 Bn.

Forecast Period 2023-30 CAGR:

15.4%

Market Size in 2030:

USD 11.73 Bn.

Segments Covered:

By Product Type

  • Software
  • Services

By Application

  • Drug Discovery
  • Drug Development
  • Other Application

By End-Users

  • Pharma & Biotech Companies
  • Contract Research Organizations
  • Academic Research Institutions
  • Regulatory Authorities

By Region

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:

  • Growth in the Development of Biologics and Biosimilar

Key Market Restraints:

  • Lack of Standardisation For Model Representation

Key Opportunities:

  • Growing Government Funding In The R&D Activities

Companies Covered in the report:

  • Certara (USA), Dassault Systemes (France), Advanced Chemistry Development (Canada), Simulation Plus (California), Schrodinger, Inc. (US), and Other major players.

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. BIOSIMULATION MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. BIOSIMULATION MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. BIOSIMULATION MARKET COMPETITIVE RIVALRY
TABLE 005. BIOSIMULATION MARKET THREAT OF NEW ENTRANTS
TABLE 006. BIOSIMULATION MARKET THREAT OF SUBSTITUTES
TABLE 007. BIOSIMULATION MARKET BY TEST TYPE
TABLE 008. ELISA MARKET OVERVIEW (2016-2028)
TABLE 009. COLORIMETRIC MARKET OVERVIEW (2016-2028)
TABLE 010. SPECTROPHOTOMETRIC MARKET OVERVIEW (2016-2028)
TABLE 011. BIOSIMULATION MARKET BY APPLICATION
TABLE 012. HOSPITAL MARKET OVERVIEW (2016-2028)
TABLE 013. LABORATORY MARKET OVERVIEW (2016-2028)
TABLE 014. NORTH AMERICA BIOSIMULATION MARKET, BY TEST TYPE (2016-2028)
TABLE 015. NORTH AMERICA BIOSIMULATION MARKET, BY APPLICATION (2016-2028)
TABLE 016. N BIOSIMULATION MARKET, BY COUNTRY (2016-2028)
TABLE 017. EUROPE BIOSIMULATION MARKET, BY TEST TYPE (2016-2028)
TABLE 018. EUROPE BIOSIMULATION MARKET, BY APPLICATION (2016-2028)
TABLE 019. BIOSIMULATION MARKET, BY COUNTRY (2016-2028)
TABLE 020. ASIA PACIFIC BIOSIMULATION MARKET, BY TEST TYPE (2016-2028)
TABLE 021. ASIA PACIFIC BIOSIMULATION MARKET, BY APPLICATION (2016-2028)
TABLE 022. BIOSIMULATION MARKET, BY COUNTRY (2016-2028)
TABLE 023. MIDDLE EAST & AFRICA BIOSIMULATION MARKET, BY TEST TYPE (2016-2028)
TABLE 024. MIDDLE EAST & AFRICA BIOSIMULATION MARKET, BY APPLICATION (2016-2028)
TABLE 025. BIOSIMULATION MARKET, BY COUNTRY (2016-2028)
TABLE 026. SOUTH AMERICA BIOSIMULATION MARKET, BY TEST TYPE (2016-2028)
TABLE 027. SOUTH AMERICA BIOSIMULATION MARKET, BY APPLICATION (2016-2028)
TABLE 028. BIOSIMULATION MARKET, BY COUNTRY (2016-2028)
TABLE 029. CERTARA: SNAPSHOT
TABLE 030. CERTARA: BUSINESS PERFORMANCE
TABLE 031. CERTARA: PRODUCT PORTFOLIO
TABLE 032. CERTARA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 032. DASSAULT SYSTEMES: SNAPSHOT
TABLE 033. DASSAULT SYSTEMES: BUSINESS PERFORMANCE
TABLE 034. DASSAULT SYSTEMES: PRODUCT PORTFOLIO
TABLE 035. DASSAULT SYSTEMES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 035. ADVANCED CHEMISTRY DEVELOPMENT: SNAPSHOT
TABLE 036. ADVANCED CHEMISTRY DEVELOPMENT: BUSINESS PERFORMANCE
TABLE 037. ADVANCED CHEMISTRY DEVELOPMENT: PRODUCT PORTFOLIO
TABLE 038. ADVANCED CHEMISTRY DEVELOPMENT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 038. SIMULATION PLUS: SNAPSHOT
TABLE 039. SIMULATION PLUS: BUSINESS PERFORMANCE
TABLE 040. SIMULATION PLUS: PRODUCT PORTFOLIO
TABLE 041. SIMULATION PLUS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 041. SCHRODINGER: SNAPSHOT
TABLE 042. SCHRODINGER: BUSINESS PERFORMANCE
TABLE 043. SCHRODINGER: PRODUCT PORTFOLIO
TABLE 044. SCHRODINGER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 044. INC.: SNAPSHOT
TABLE 045. INC.: BUSINESS PERFORMANCE
TABLE 046. INC.: PRODUCT PORTFOLIO
TABLE 047. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 047. CHEMICAL COMPUTING GROUP ULC: SNAPSHOT
TABLE 048. CHEMICAL COMPUTING GROUP ULC: BUSINESS PERFORMANCE
TABLE 049. CHEMICAL COMPUTING GROUP ULC: PRODUCT PORTFOLIO
TABLE 050. CHEMICAL COMPUTING GROUP ULC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 050. PHYSIOMICS PLC: SNAPSHOT
TABLE 051. PHYSIOMICS PLC: BUSINESS PERFORMANCE
TABLE 052. PHYSIOMICS PLC: PRODUCT PORTFOLIO
TABLE 053. PHYSIOMICS PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. ROSA & CO. LLC: SNAPSHOT
TABLE 054. ROSA & CO. LLC: BUSINESS PERFORMANCE
TABLE 055. ROSA & CO. LLC: PRODUCT PORTFOLIO
TABLE 056. ROSA & CO. LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. BIOSIMULATION CONSULTING INC.: SNAPSHOT
TABLE 057. BIOSIMULATION CONSULTING INC.: BUSINESS PERFORMANCE
TABLE 058. BIOSIMULATION CONSULTING INC.: PRODUCT PORTFOLIO
TABLE 059. BIOSIMULATION CONSULTING INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. GENEDATA AG: SNAPSHOT
TABLE 060. GENEDATA AG: BUSINESS PERFORMANCE
TABLE 061. GENEDATA AG: PRODUCT PORTFOLIO
TABLE 062. GENEDATA AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. INSTEM GROUP OF COMPANIES: SNAPSHOT
TABLE 063. INSTEM GROUP OF COMPANIES: BUSINESS PERFORMANCE
TABLE 064. INSTEM GROUP OF COMPANIES: PRODUCT PORTFOLIO
TABLE 065. INSTEM GROUP OF COMPANIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. PPD INC.: SNAPSHOT
TABLE 066. PPD INC.: BUSINESS PERFORMANCE
TABLE 067. PPD INC.: PRODUCT PORTFOLIO
TABLE 068. PPD INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. YOKOGAWA INSILICO BIOTECHNOLOGY GMBH: SNAPSHOT
TABLE 069. YOKOGAWA INSILICO BIOTECHNOLOGY GMBH: BUSINESS PERFORMANCE
TABLE 070. YOKOGAWA INSILICO BIOTECHNOLOGY GMBH: PRODUCT PORTFOLIO
TABLE 071. YOKOGAWA INSILICO BIOTECHNOLOGY GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 071. IMMUNETRICS: SNAPSHOT
TABLE 072. IMMUNETRICS: BUSINESS PERFORMANCE
TABLE 073. IMMUNETRICS: PRODUCT PORTFOLIO
TABLE 074. IMMUNETRICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 074. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 075. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 076. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 077. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. BIOSIMULATION MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. BIOSIMULATION MARKET OVERVIEW BY TEST TYPE
FIGURE 012. ELISA MARKET OVERVIEW (2016-2028)
FIGURE 013. COLORIMETRIC MARKET OVERVIEW (2016-2028)
FIGURE 014. SPECTROPHOTOMETRIC MARKET OVERVIEW (2016-2028)
FIGURE 015. BIOSIMULATION MARKET OVERVIEW BY APPLICATION
FIGURE 016. HOSPITAL MARKET OVERVIEW (2016-2028)
FIGURE 017. LABORATORY MARKET OVERVIEW (2016-2028)
FIGURE 018. NORTH AMERICA BIOSIMULATION MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 019. EUROPE BIOSIMULATION MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 020. ASIA PACIFIC BIOSIMULATION MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 021. MIDDLE EAST & AFRICA BIOSIMULATION MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 022. SOUTH AMERICA BIOSIMULATION MARKET OVERVIEW BY COUNTRY (2016-2028)

Please Wait...

Frequently Asked Questions :

What would be forecast period in the Biosimulation Market research report?

The forecast period in the Biosimulation Market research report is 2023-2030.

Who are the key players in Biosimulation Market?

Certara (USA), Dassault Systemes (France), Advanced Chemistry Development (Canada), Simulation Plus (California), Schrodinger, Inc. (US), Chemical Computing Group ULC (Canada), Physiomics Plc (UK), Rosa & Co. LLC (US), BioSimulation Consulting Inc., Genedata AG (Switzerland), Instem Group of Companies (USA), PPD, Inc. (North Carolina), Yokogawa Insilico Biotechnology GmbH (Germany), Immunetrics (US), and other major players.

What are the segments of Biosimulation Market?

The Biosimulation Market is segmented into Product Type, Application, End-Users, and region. By Product Type the market is categorized into Software, Services. By Application, the market is categorized into Drug Discovery, Drug Development, and Other Application. By End-Users, the market is categorized into Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions, Regulatory Authorities. By region, it is analysed across North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain etc.), Asia-Pacific (China; India; Japan; Southeast Asia etc.), South America (Brazil; Argentina etc.), Middle East & Africa (Saudi Arabia; South Africa etc.).

What is the Biosimulation Market?

Biosimulation is a predictive technological tool that is used in the discovery stage which signifies the future outcomes of the current experimental trials. It is also referred to as model-based drug development and it has the ability to make a data-driven decision at all stages of drug development by using the quantitative framework.

How big is the Biosimulation Market?

The global Biosimulation Market size was valued at USD 3.73 Billion in 2022 and is projected to reach USD 11.73 Billion by 2030, growing at a CAGR of 15.4% from 2023 to 2030.